Drugs / MB02
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 2 met primary | ||||||
| Phase 1 | NCT04238663 | Sep 2019 → Mar 2020 | — | mAbxience Research S.L. | Completed | Met primary |
| Phase 1 | NCT04238650 | Aug → Dec 2019 | — | mAbxience Research S.L. | Completed | Met primary |
| Phase 1 | NCT03293654 | Dec 2017 → May 2019 | — | mAbxience Research S.L. | Completed | Mixed |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03296163 | Feb 2018 → Jul 2019 | non-small cell lung carcinoma | mAbxience Research S.L. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03293654 ↗ |
| Known as | MB02 (Bevacizumab Biosimilar) | “MB02 (Bevacizumab Biosimilar)” NCT03293654 ↗ |
| Route | Intravenous | “intravenous infusion” NCT03293654 ↗ |